IBRX News

Pomerantz LLP Advises of Securities Class Action Against ImmunityBio, Inc. – IBRX

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ImmunityBio, Inc. (IBRX) and Encourages Investors to Learn More About the Investigation

IBRX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ImmunityBio, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

ImmunityBio, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IBRX

IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm

ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by The Firm - IBRX

IBRX SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on Behalf of ImmunityBio, Inc. Investors - Contact Kirby McInerney LLP by May 26, 2026

ImmunityBio, Inc. (IBRX) Faces Securities Class Action Amid FDA Warning Regarding Unsupported Cancer Treatment Claims, $2 Billion Market Capitalization Wiped Out -- Hagens Berman

Deadline Approaching: ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith